vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -6.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -7.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
ESPR vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $205.2M |
| Net Profit | — | — |
| Gross Margin | — | 16.2% |
| Operating Margin | 50.6% | -14.4% |
| Net Margin | — | — |
| Revenue YoY | 143.7% | -6.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $205.2M | ||
| Q3 25 | $87.3M | $210.3M | ||
| Q2 25 | $82.4M | $228.0M | ||
| Q1 25 | $65.0M | $217.9M | ||
| Q4 24 | $69.1M | $218.2M | ||
| Q3 24 | $51.6M | $213.8M | ||
| Q2 24 | $73.8M | $237.1M | ||
| Q1 24 | $137.7M | $239.2M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $-9.4M | ||
| Q2 25 | $-12.7M | $-9.4M | ||
| Q1 25 | $-40.5M | $-7.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-7.1M | ||
| Q2 24 | $-61.9M | $2.8M | ||
| Q1 24 | $61.0M | $-6.1M |
| Q4 25 | — | 16.2% | ||
| Q3 25 | — | 20.3% | ||
| Q2 25 | — | 21.5% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | — | 19.5% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 22.7% | ||
| Q1 24 | — | 20.2% |
| Q4 25 | 50.6% | -14.4% | ||
| Q3 25 | -11.4% | -1.6% | ||
| Q2 25 | 8.6% | -1.1% | ||
| Q1 25 | -34.0% | -1.5% | ||
| Q4 24 | -6.4% | -2.0% | ||
| Q3 24 | -31.0% | 0.1% | ||
| Q2 24 | 3.5% | 1.4% | ||
| Q1 24 | 52.5% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | -4.5% | ||
| Q2 25 | -15.4% | -4.1% | ||
| Q1 25 | -62.2% | -3.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -3.3% | ||
| Q2 24 | -83.9% | 1.2% | ||
| Q1 24 | 44.3% | -2.6% |
| Q4 25 | $0.32 | $-2.76 | ||
| Q3 25 | $-0.16 | $-0.34 | ||
| Q2 25 | $-0.06 | $-0.34 | ||
| Q1 25 | $-0.21 | $-0.26 | ||
| Q4 24 | $-0.14 | $-0.22 | ||
| Q3 24 | $-0.15 | $-0.26 | ||
| Q2 24 | $-0.33 | $0.10 | ||
| Q1 24 | $0.34 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $66.3M |
| Total DebtLower is stronger | — | $180.9M |
| Stockholders' EquityBook value | $-302.0M | $179.8M |
| Total Assets | $465.9M | $551.2M |
| Debt / EquityLower = less leverage | — | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $66.3M | ||
| Q3 25 | $92.4M | $54.0M | ||
| Q2 25 | $86.1M | $49.8M | ||
| Q1 25 | $114.6M | $79.1M | ||
| Q4 24 | $144.8M | $71.8M | ||
| Q3 24 | $144.7M | $54.1M | ||
| Q2 24 | $189.3M | $42.1M | ||
| Q1 24 | $226.6M | $48.4M |
| Q4 25 | — | $180.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $179.8M | ||
| Q3 25 | $-451.4M | $251.2M | ||
| Q2 25 | $-433.5M | $260.5M | ||
| Q1 25 | $-426.2M | $253.1M | ||
| Q4 24 | $-388.7M | $245.3M | ||
| Q3 24 | $-370.2M | $271.4M | ||
| Q2 24 | $-344.2M | $270.5M | ||
| Q1 24 | $-294.3M | $277.3M |
| Q4 25 | $465.9M | $551.2M | ||
| Q3 25 | $364.0M | $632.1M | ||
| Q2 25 | $347.1M | $639.4M | ||
| Q1 25 | $324.0M | $657.4M | ||
| Q4 24 | $343.8M | $621.6M | ||
| Q3 24 | $314.1M | $662.5M | ||
| Q2 24 | $352.3M | $666.7M | ||
| Q1 24 | $373.1M | $675.4M |
| Q4 25 | — | 1.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $8.8M |
| Free Cash FlowOCF − Capex | — | $2.6M |
| FCF MarginFCF / Revenue | — | 1.3% |
| Capex IntensityCapex / Revenue | 0.0% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $8.8M | ||
| Q3 25 | $-4.3M | $3.6M | ||
| Q2 25 | $-31.4M | $10.7M | ||
| Q1 25 | $-22.6M | $10.9M | ||
| Q4 24 | $-35.0M | $19.2M | ||
| Q3 24 | $-35.3M | $10.8M | ||
| Q2 24 | $-7.2M | $8.7M | ||
| Q1 24 | $53.8M | $9.1M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $-2.7M | ||
| Q2 25 | — | $7.4M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $14.0M | ||
| Q3 24 | $-35.5M | $4.6M | ||
| Q2 24 | $-7.3M | $1.5M | ||
| Q1 24 | $53.8M | $3.3M |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | -1.3% | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | -68.7% | 2.2% | ||
| Q2 24 | -9.9% | 0.6% | ||
| Q1 24 | 39.0% | 1.4% |
| Q4 25 | 0.0% | 3.0% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.3% | 2.9% | ||
| Q2 24 | 0.1% | 3.0% | ||
| Q1 24 | 0.1% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.11× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
